# Efficacy 2 Part Study of Identification of Keloid Biomarkers and Effect of QAX576 on Keloid Recurrence

> **NCT00987545** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 3 (actual)

## Conditions studied

- Keloids

## Interventions

- **DRUG:** QAX576
- **DRUG:** QAX576 placebo

## Key facts

- **NCT ID:** NCT00987545
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-06
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Negative pharmacodynamics due to lack of Interleukin-13 signature in biomarker data from Part I of the study.
- **Last updated:** 2020-12-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00987545

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00987545, "Efficacy 2 Part Study of Identification of Keloid Biomarkers and Effect of QAX576 on Keloid Recurrence". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00987545. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*